Sydney cancer immunotherapy research company, Imugene has presented positive vaccine trial results at the Annual American Association for Cancer Research. The results were released after a trial period on a genetically identical mouse-model subject with HER-2+ breast cancer. B-cell cancer growth was inhibited in the test subject after implementation of the newly developed
mimitope programmed cell death protein (PD-1).
The PD-1 elicited an antibody response in the mouse that inhibited growth of the cancer tumor.
Imugene collaborated with the Medical University of Vienna at the Annual American during the trial tests.
Please read the announcement attached.